Genetically-engineered oncolytic viruses are an emerging class of cancer therapeutics which have shown significant clinical promise in the recent years. My research focuses on exploration of oncolytic viruses for cancer immunotherapy. Specifically, I am using engineered Newcastle Disease Virus (NDV) to study the mechanisms of anti-tumor immunity induced by viruses and to develop novel anti-cancer agents. My main area of interest is exploring different immunotherapeutic strategies that could circumvent the limitations of oncolytic viruses and make oncolytic virus-based therapy applicable to all cancer types.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dmitriy Zamarin discloses the following relationships and financial interests:
-
Accurius Therapeutics, Inc.
Ownership / Equity Interests; Provision of Services (uncompensated) -
Calidi Biotherapeutics
Ownership / Equity Interests; Provision of Services (uncompensated) -
Celldex Therapeutics
Provision of Services -
Crown Bioscience Inc.
Provision of Services -
Defined Health
Provision of Services -
GlaxoSmithKline
Provision of Services -
Hookipa Biotech
Provision of Services -
ImmunOs Therapeutics AG
Ownership / Equity Interests; Provision of Services (uncompensated)
-
Mana Therapeutics, Inc.
Provision of Services -
Memgen, Inc.
Provision of Services -
Merck & Co Inc.
Intellectual Property Rights -
Projects In Knowledge
Provision of Services -
Roche
Provision of Services -
Synthekine, Inc.
Provision of Services -
Tessa Therapeutics
Provision of Services -
Xencor, Inc.
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
View all disclosures